Long-term safety of felzartamab for kidney transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the Week 52 visit in the main study (or are about to finish it).
- You received at least one dose of felzartamab in the main study, even if you later stopped treatment.
- If you are still getting felzartamab, your doctor thinks continuing is a good idea.
- You did not meet a rule that would have forced you to stop treatment in the main study (but kept going anyway).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called felzartamab to see if it can help people who have a type of kidney inflammation after a transplant, even without donor-specific antibodies. It might offer a new treatment option for those who are not getting better on their own.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This trial tests a new two-step treatment for a type of long-term kidney rejection (chronic active antibody-mediated rejection) in transplant recipients. First, you receive an infusion of CD38 antibodies to clear harmful cells, then a months-long course of azathioprine pills to maintain the benefit and protect your kidney.
This study tests an investigational drug called felzartamab to see if it can help control thyroid function in adults with Graves' disease. It may offer a new option if you are still having symptoms despite anti-thyroid medication.
This is a long-term follow-up study for people who have already completed a study of the drug tegoprubart after a kidney transplant. It checks how safe and effective the drug is over a longer period.
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
Hear when a new Antibody-mediated Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.